ICER, CADTH, and NICE collaborate to increase transparency in health technology evaluations
The Institute for Clinical and Economic Review (ICER), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the UK’s National Institute for Health and Care Excellence (NICE) have announced changes to the way confidential information about health technologies is handled. The aim is to streamline processes and increase transparency while balancing the need to protect confidential information. The three organizations have been working together to create a more consistent approach to handling clinical data. ICER has updated its academic-in-confidence data policy, reducing the period during which data is redacted from external and public documents from 18 months to 12 months. These changes will come into effect in May 2023.
Recent Posts
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions
CTX310 Breakthrough in Lipid Disorder Treatment
CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients
European Commission Approves Koselugo for Adult NF1 Patients
The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Efficiency
UK Clinical Trial Reforms Slash Approval Times
UK Clinical Trial Reforms have accelerated clinical trial approvals, reducing average times from 91 days to 41 days through risk-proportionate changes at the Medicines and Healthcare produ...